NCT06302621 2026-01-15
Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
Massachusetts General Hospital
Phase 1 Recruiting
Clinical Trials
4 trialsNCT04463771 2025-12-10
POD1UM-204
Incyte Corporation
Phase 2 Active not recruiting
NCT04003610 2025-11-04
Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)
Incyte Corporation
Phase 2 Terminated
NCT04003623 2022-05-10
Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208)
Incyte Corporation
Phase 2 Terminated